In the first-line setting, SMARCA4 mutations were associated with significantly worse OS to first-line CIT treatment in non-squamous NSCLC (SMARCA4-mutated 8.1 months vs. SMARCA4 WT 15.0 months (p < 0.001) [22]. The gene discussed is SMARCA4; the disease is non-small cell lung carcinoma.